Immunic, Inc. Engages in Key Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: PRnewswire
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will significantly influence the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is also developing earlier-stage programs like IMU-856 and IMU-381, aimed at creating a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing its competitive edge in the biotech sector.
- Market Risk Warning: The company’s press release includes forward-looking statements that involve significant risks and uncertainties, such as inflation and geopolitical conflicts that may impact clinical trial progress, urging investors to carefully assess these associated risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.070
Low
3.00
Averages
4.25
High
8.00
Current: 13.070
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic, Inc. Engages in Key Conferences
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will significantly influence the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is also developing earlier-stage programs like IMU-856 and IMU-381, aimed at creating a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing its competitive edge in the biotech sector.
- Market Risk Warning: The company’s press release includes forward-looking statements that involve significant risks and uncertainties, such as inflation and geopolitical conflicts that may impact clinical trial progress, urging investors to carefully assess these associated risks.
See More
Immunic to Participate in Multiple Conferences
- Investor Conference Participation: Immunic's CEO Erik Lundgren and COO Jason Tardio will engage in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, showcasing the company's advancements in neurologic disease treatments, which is expected to attract investor interest and boost market confidence.
- BIO International Convention Activities: The Immunic management team will participate in partnering activities at the BIO International Convention in San Diego from June 22-25, aiming to expand connections with potential partners and accelerate the market introduction of its neurologic disease therapies.
- Drug Development Presentation: At the EFMC-ACSMEDI Medicinal Chemistry Frontiers Symposium from June 22-25, Immunic's Global Head of Intellectual Property, Christian Gege, will present research on IMU-856, further solidifying the company's leadership in innovative drug development.
- European Academy of Neurology Congress Participation: Immunic's medical team will be present at the 12th Congress of the European Academy of Neurology in Geneva from June 27-30, providing direct engagement opportunities with industry experts to enhance the company's influence in the neurology field.
See More
Immunic Presents New Data Highlighting Efficacy of Vidofludimus Calcium
- New Statistical Analysis: Immunic introduced a novel unified statistical analysis method at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting, aimed at assessing treatment effects by capturing confirmed disability changes, which may enhance statistical power in future clinical trials and provide a more comprehensive evaluation of treatment benefits for patients.
- Patient-Reported Outcomes: In the CALLIPER trial, changes in depressive symptoms (PHQ-9 scores) were similar between vidofludimus calcium and placebo, while treatment satisfaction scores favored vidofludimus calcium at both 48 and 120 weeks, indicating its superior perceived effectiveness among patients.
- Safety and Tolerability: Among 467 patients, the incidence of treatment-emergent adverse events for vidofludimus calcium was 69.4%, comparable to 68.5% for placebo, demonstrating a favorable safety and tolerability profile that supports its continued development in multiple sclerosis patients.
- Positive Clinical Signals: Post-hoc analyses from the CALLIPER trial indicated significant effects of vidofludimus calcium on confirmed disability improvement, and combined with its favorable safety profile, this strengthens confidence in its potential as a treatment for multiple sclerosis.
See More
Immunic Presents New Data Highlighting Efficacy of Vidofludimus Calcium
- Clinical Trial Data Presentation: Immunic showcased new data from its phase 2 CALLIPER trial at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting, emphasizing the potential of Vidofludimus calcium in treating progressive multiple sclerosis, which could enhance the company's market position in neurological diseases.
- Innovative Assessment Method: The newly presented poster introduces a unified statistical analysis method that captures both confirmed disability worsening and improvement, providing a more comprehensive assessment of disability changes, potentially improving statistical power in future clinical trials.
- Patient-Reported Outcomes: Phase 2 trial data indicates that Vidofludimus calcium shows favorable results in patient-reported depressive symptoms and treatment satisfaction, particularly at weeks 48 and 120, where satisfaction scores significantly exceeded those of the placebo group, demonstrating good patient acceptance.
- Safety and Tolerability: Among 467 patients, the incidence of treatment-emergent adverse events for Vidofludimus calcium was comparable to placebo, supporting its safety and tolerability profile in progressive multiple sclerosis patients, thereby enhancing confidence in its market promotion.
See More
Immunic Appoints Erik Lundgren as CEO Effective May 2026
- New CEO Appointment: Immunic has appointed Erik Lundgren as CEO effective May 22, 2026, with his employment starting on June 1, 2026, succeeding Daniel Vitt, Ph.D., who will continue to oversee scientific strategy and portfolio advancement, ensuring stability and continuity in leadership.
- Clinical Development Focus: Lundgren will lead Immunic in advancing vidofludimus calcium through late-stage clinical development, particularly the pivotal phase 3 ENSURE program for relapsing multiple sclerosis and the planned phase 3 program for primary progressive multiple sclerosis, aiming to expedite new drug application submissions and regulatory approvals to enhance market competitiveness.
- Commercial Strategy Expertise: Having served as Senior Vice President at Genentech, Lundgren oversaw the commercial strategy across the company's broad portfolio, bringing valuable industry experience that will aid in driving product commercialization at Immunic.
- Investor Confidence Boost: Immunic recently received a Buy rating from Guggenheim, reflecting market confidence in its lead asset, and with Lundgren's appointment, it is expected to further enhance investor expectations and confidence in the company's future growth.
See More
Immunic Appoints New CEO to Drive Growth
- Leadership Change: Immunic, Inc. appointed Erik Lundgren as CEO effective May 22, 2026, succeeding Daniel Vitt, who will continue to oversee scientific strategy, reflecting the company's commitment to transitioning into a commercial-stage entity.
- Clinical Development Advancement: Lundgren will lead the advancement of vidofludimus calcium through late-stage clinical development, particularly the pivotal phase 3 ENSURE program for relapsing multiple sclerosis, with significant data expected by year-end, potentially laying the groundwork for commercialization.
- Market Potential: Lundgren emphasized the unique therapeutic profile of vidofludimus calcium, which targets both immunological and neuroprotective pathways, addressing the urgent market need for treatments that slow disability progression, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Equity Incentive Plan: As an inducement for his employment, Immunic's Board granted Lundgren options to purchase 1 million shares of common stock, vesting over four years, demonstrating the company's high regard for his leadership capabilities and future contributions.
See More
Immunic, Inc. Engages in Key Conferences
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will significantly influence the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is also developing earlier-stage programs like IMU-856 and IMU-381, aimed at creating a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing its competitive edge in the biotech sector.
- Market Risk Warning: The company’s press release includes forward-looking statements that involve significant risks and uncertainties, such as inflation and geopolitical conflicts that may impact clinical trial progress, urging investors to carefully assess these associated risks.
See More
Immunic to Participate in Multiple Conferences
- Investor Conference Participation: Immunic's CEO Erik Lundgren and COO Jason Tardio will engage in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, showcasing the company's advancements in neurologic disease treatments, which is expected to attract investor interest and boost market confidence.
- BIO International Convention Activities: The Immunic management team will participate in partnering activities at the BIO International Convention in San Diego from June 22-25, aiming to expand connections with potential partners and accelerate the market introduction of its neurologic disease therapies.
- Drug Development Presentation: At the EFMC-ACSMEDI Medicinal Chemistry Frontiers Symposium from June 22-25, Immunic's Global Head of Intellectual Property, Christian Gege, will present research on IMU-856, further solidifying the company's leadership in innovative drug development.
- European Academy of Neurology Congress Participation: Immunic's medical team will be present at the 12th Congress of the European Academy of Neurology in Geneva from June 27-30, providing direct engagement opportunities with industry experts to enhance the company's influence in the neurology field.
See More
Immunic Presents New Data Highlighting Efficacy of Vidofludimus Calcium
- New Statistical Analysis: Immunic introduced a novel unified statistical analysis method at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting, aimed at assessing treatment effects by capturing confirmed disability changes, which may enhance statistical power in future clinical trials and provide a more comprehensive evaluation of treatment benefits for patients.
- Patient-Reported Outcomes: In the CALLIPER trial, changes in depressive symptoms (PHQ-9 scores) were similar between vidofludimus calcium and placebo, while treatment satisfaction scores favored vidofludimus calcium at both 48 and 120 weeks, indicating its superior perceived effectiveness among patients.
- Safety and Tolerability: Among 467 patients, the incidence of treatment-emergent adverse events for vidofludimus calcium was 69.4%, comparable to 68.5% for placebo, demonstrating a favorable safety and tolerability profile that supports its continued development in multiple sclerosis patients.
- Positive Clinical Signals: Post-hoc analyses from the CALLIPER trial indicated significant effects of vidofludimus calcium on confirmed disability improvement, and combined with its favorable safety profile, this strengthens confidence in its potential as a treatment for multiple sclerosis.
See More
Immunic Presents New Data Highlighting Efficacy of Vidofludimus Calcium
- Clinical Trial Data Presentation: Immunic showcased new data from its phase 2 CALLIPER trial at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting, emphasizing the potential of Vidofludimus calcium in treating progressive multiple sclerosis, which could enhance the company's market position in neurological diseases.
- Innovative Assessment Method: The newly presented poster introduces a unified statistical analysis method that captures both confirmed disability worsening and improvement, providing a more comprehensive assessment of disability changes, potentially improving statistical power in future clinical trials.
- Patient-Reported Outcomes: Phase 2 trial data indicates that Vidofludimus calcium shows favorable results in patient-reported depressive symptoms and treatment satisfaction, particularly at weeks 48 and 120, where satisfaction scores significantly exceeded those of the placebo group, demonstrating good patient acceptance.
- Safety and Tolerability: Among 467 patients, the incidence of treatment-emergent adverse events for Vidofludimus calcium was comparable to placebo, supporting its safety and tolerability profile in progressive multiple sclerosis patients, thereby enhancing confidence in its market promotion.
See More
Immunic Appoints Erik Lundgren as CEO Effective May 2026
- New CEO Appointment: Immunic has appointed Erik Lundgren as CEO effective May 22, 2026, with his employment starting on June 1, 2026, succeeding Daniel Vitt, Ph.D., who will continue to oversee scientific strategy and portfolio advancement, ensuring stability and continuity in leadership.
- Clinical Development Focus: Lundgren will lead Immunic in advancing vidofludimus calcium through late-stage clinical development, particularly the pivotal phase 3 ENSURE program for relapsing multiple sclerosis and the planned phase 3 program for primary progressive multiple sclerosis, aiming to expedite new drug application submissions and regulatory approvals to enhance market competitiveness.
- Commercial Strategy Expertise: Having served as Senior Vice President at Genentech, Lundgren oversaw the commercial strategy across the company's broad portfolio, bringing valuable industry experience that will aid in driving product commercialization at Immunic.
- Investor Confidence Boost: Immunic recently received a Buy rating from Guggenheim, reflecting market confidence in its lead asset, and with Lundgren's appointment, it is expected to further enhance investor expectations and confidence in the company's future growth.
See More
Immunic Appoints New CEO to Drive Growth
- Leadership Change: Immunic, Inc. appointed Erik Lundgren as CEO effective May 22, 2026, succeeding Daniel Vitt, who will continue to oversee scientific strategy, reflecting the company's commitment to transitioning into a commercial-stage entity.
- Clinical Development Advancement: Lundgren will lead the advancement of vidofludimus calcium through late-stage clinical development, particularly the pivotal phase 3 ENSURE program for relapsing multiple sclerosis, with significant data expected by year-end, potentially laying the groundwork for commercialization.
- Market Potential: Lundgren emphasized the unique therapeutic profile of vidofludimus calcium, which targets both immunological and neuroprotective pathways, addressing the urgent market need for treatments that slow disability progression, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Equity Incentive Plan: As an inducement for his employment, Immunic's Board granted Lundgren options to purchase 1 million shares of common stock, vesting over four years, demonstrating the company's high regard for his leadership capabilities and future contributions.
See More
